Trump fast-tracks psychedelic drug research

In a significant policy shift, President Donald Trump has directed the FDA to expedite the review of previously restricted psychedelic substances for medical use.

The executive order specifically highlights ibogaine, a plant-based drug that has gained support among veteran groups for its potential to treat addiction and depression.

During the Oval Office signing, Trump was joined by Joe Rogan and Robert F. Kennedy Jr., both of whom have advocated for alternative mental health therapies.

While the move is praised by some advocates, health experts have cautioned about the serious cardiac risks associated with unregulated psychedelic use.